Archive · 17 Aug 2025
Aurobindo Pharma China Facility to Break Even in FY26
Aurobindo Pharma, a medicine maker, is expanding its operations.
They built a factory in China and expect it to start making a profit by the end of this fiscal year.
The company spent a large amount of money on it.
The company is also investing in factories in the US.
They plan to sell more medicine in the US and Europe to make more money.
Although the company recently made less profit, they expect to improve their finances in the coming year.
Aurobindo Pharma's China facility expects to break even by Q3 FY26.
The China facility began operations in late November 2024.
The company invested approximately USD 145 million in the China facility.
Aurobindo Pharma invested about USD 70 million in two US facilities, with production expected this fiscal year.
The company plans to file over 20 products in the US and Europe from its Visakhapatnam plant.
- Who
- Aurobindo Pharma.
- What
- Aurobindo Pharma expects its China facility to break even at the EBITDA level by Q3 FY26.
- When
- The China facility is expected to break even at the EBITDA level by Q3 FY26.
- Where
- The company's China facility.
- Why
- To increase revenue and improve profit margins.
- China Facility Investment
- USD 145 million
- China Facility Operations Start
- November 2024
- US Facilities Investment
- USD 70 million
- Visakhapatnam Plant Products
- More than 20 planned filings
- FY26 Target Margin
- 20-21 percent